Protein scaffolds: The next generation of protein therapeutics?

BioProcess International

Volumn 11, Issue 2, 2013, Pages

  Mintz, Clifford S ^a   Crea, Roberto ^b  

^a BioInsights Inc   (United States)

^b CEO of Protelica ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; ETANERCEPT; GEMTUZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; MYLOTARQ; NATALIZUMAB; NIMOTUZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; ORTHOCLONE OKT 3; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; SOLRIS; SYNGIS; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ACUTE GRAFT REJECTION; ACUTE GRANULOCYTIC LEUKEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CROHN DISEASE; DISULFIDE BOND; DRUG EFFICACY; DRUG MARKETING; EXUDATIVE MACULAR DEGENERATION; GLIOBLASTOMA; GLIOMA; GLYCOSYLATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INVESTMENT; KIDNEY CANCER; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POSTMENOPAUSE OSTEOPOROSIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SEVERE PERSISTENT ASTHMA; SQUAMOUS CELL CARCINOMA;

EID: 84874679121     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (44)

1. Reichert JM. Antibodies to Watch in 2010. MAbs 2(1) 2010: 84-100.
2. Reichert J. Marketed Therapeutic Antibodies Compendium. MAbs 4(3) 2012: 413-415.
3. Carroll JD. The 15-Best Selling Drugs of 2012. FiercePharma 9 October 2012; www.fiercepharma.com/special-reports/humira-0.
4. Scolnik PA. MAbs: A Business Perspective. MAbs 1(2) 2009: 179-184.
5. Gebauer M, Skerra A. Engineered Protein Scaffolds as Next-Generation Antibody Therapeutics. Curr. Opin. Chem. Biol. 13(3) 2009: 245-255.
6. Steinmeyer DE, McCormick EL. The Art of Antibody Process Development. Drug Discov. Today 13(13-14) 2008: 613-618.
7. Beck A, Wurch T, Corvaia N. Therapeutic Antibodies and Derivatives: From the Bench to the Clinic. Curr. Pharm. Biotechnol. 9(6) 2008: 421-422.
8. Wurch T, Pierre A, Depil S. Novel Protein Scaffolds as Emerging Therapeutic Proteins: From Discovery to Clinical Proof-of-Concept. Trends Biotechnol. 30(11) 2012: 575-582.
9. Kontermann RE. Alternative Antibody Formats. Curr. Opin. Mol. Ther. 12(2) 2010: 176-183.
10. Huston JS, et al. Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli. Proc. Natl. Acad. Sci. 85(16) 1988: 5879-5883.
11. Dimitrov DS. Engineered CH2 Domains (Nanoantibodies). MAbs 1(1) 2009: 26-28.
12. Gehlsen K, et al. Pharmacokinetics of Engineered Human Monomeric and Dimeric CH2 Domains. MAbs 4(4) 2012: 466-474.
13. Marco D. Biotechnological Applications of Recombinant Single-Domain Antibody Fragments. Microbial Cell Factories 10(44) 2011: 7-14.
14. Koide A, et al. Teaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 Scaffold. J. Mol. Biol. 415(2) 2012: 393-405.
15. Nixon AE, Wood CR. Engineered Protein Inhibitors of Proteases. Curr. Opin. Drug Discov. Devel. 9(2) 2006: 261-268.
16. Stumpp MT, Binz HK, Amstutz P. DARPins: A New Generation of Protein Therapeutics. Drug Discov. Today 13(15-16) 2008: 695-701.
17. Zahnd C, et al. Efficient Tumor Targeting with High-Affinity-Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size. Cancer Res. 70(4) 2010: 1595-1605.
18. Silverman J, et al. Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains. Nat. Biotechnol. 23(12) 2005: 1556-1561. (Pubitemid 41752934)
19. Skerra A. Alternative Binding Proteins: Anticalins - Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activities. FEBS J. 275(11) 2008: 2677-2683. (Pubitemid 351678679)
20. Kolmar H, Skerra A. Alternative Binding Proteins Get Mature: Rivalling Antibodies. FEBS J. 275(11) 2008: 2667. (Pubitemid 351678677)
21. Nygren PA. Alternative Binding Proteins: Affibody Binding Proteins Developed from a Small Three-Helix Bundle Scaffold. FEBS J. 275(11) 2008: 2668-2676.
22. Koide A, Koide S. Monobodies: Antibody Mimics Based On the Scaffold of the Fibronectin Type III Domain. Methods Mol. Biol. 352, 2007: 95-109.
23. Grabulovski D, Kaspar M, Neri D. A Novel, Non-Immunogenic Fyn SH3-Derived Binding Protein with Tumor Vascular Targeting Properties. J. Biol. Chem. 282(5) 2007: 3196-3204. (Pubitemid 47084313)
24. Krehenbrink M, et al. Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PulD. J. Mol. Biol. 383(5) 2008: 1058-1068.
25. Ebersbach H, et al. Affilin-Novel Binding Molecules Based On Human Gamma-β-Crystallin: An All Beta-Sheet Protein. J. Mol. Biol. 372(1) 2007: 172-185. (Pubitemid 47223227)
26. Lehmann A. Ecallantide (DX-88): A Plasma Kallikrein Inhibitor for the Treatment of Hereditary Angioedema and the Prevention of Blood Loss in On-Pump Cardiothoracic Surgery. Expert Opin. Biol. Ther. 8(8) 2008: 1187-1199.
27. Waknine Y. FDA Approves Ecallantide for Hereditary Angioedema. Medscape 4 December 2009.
28. Devy L, et al. PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor. Neoplasia 9(11) 2007: 927-937. (Pubitemid 350086438)
29. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat. Rev. Drug. Discov. 9(3) 2010: 189-190.
30. Tawara K, Oxford JT, Jorcyk CL. Clinical Significance of Interleukin (IL)-6 in Cancer Metastasis to Bone: Potential of Anti-IL-6 Therapies. Cancer Manag. Res. 3, 2011: 177-189.
31. Orlova A, et al. (186)Re-maSGS-Z (HER2:342): A Potential Affibody Conjugate for Systemic Therapy of HER2-Expressing Tumours. Eur. J. Nucl. Med. Mol. Imaging 37(2) 2010: 260-269.
32. Tolmachev V, et al. A HER2-Binding Affibody Molecule Labeled with 68Ga for PET Imaging: Direct in vivo Comparison with the 111In-Labeled Analogue. Eur. J. Nucl. Med. Mol. Imaging 37(7) 2010: 1356-1367.
33. Tolmachev V, et al. Optimal Specific Radioactivity of Anti-HER2 Affibody Molecules Enables Discrimination between Xenografts with High and Low HER2 Expression Levels. Eur. J. Nucl. Med. Mol. Imaging 38(3) 2011: 531-539.
34. Tolmachev V, et al. Imaging of EGFR Expression in Murine Xenografts Using Site-Specifically Labeled Anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody Molecule: Aspect of the Injected Tracer Amount. Eur. J. Nucl. Med. Mo.l Imaging 37(3) 2010: 613-622.
35. Dineen SP, et al. The Adnectin CT-322 Is a Novel VEGF Receptor 2 Inhibitor That Decreases Tumor Burden in an Orthotopic Mouse Model of Pancreatic Cancer. BMC Cancer 8, 2008: 352.
36. Mamluk R, et al. Antitumor Effect of CT-322 as an Adnectin Inhibitor of Vascular Endothelial Growth Factor Receptor-2. MAbs 2(2) 2010: 199-208.
37. Sweeney CJCE, et al. Phase 1 Study of CT-322: First Adnectin Protein Therapeutic and Potent Inhibitor of VEGFR-2 in Patients with Advanced Solid Tumors. J. Clin. Oncol. 26, 2008: 3523.
38. Tolcher AW, et al. Phase I and Pharmacokinetic Study of CT-322 (BMS-844203): A Targeted Adnectin Inhibitor of VEGFR-2 Based On a Domain of Human Fibronectin. Clin Cancer Res 17(2) 2011: 363-371.
39. BMS, Trial Details for Trial CA196-004. 2012; www.cancer.gov/ clinicaltrials/search/view?cdrid=637211&version=HealthProfessional& protocolsearchid=8232863.
40. Protelica: A Next-Generation Protein Platform for the Postantibody Era Pronectin™ Technology Summary. 2012.
41. Schellenberger V, et al. A Recombinant Polypeptide Extends the in vivo Half-Life of Peptides and Proteins in a Tunable Manner. Nat. Biotechnol. 27(12) 2009: 1186-1190.
42. Fishburn CS. The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics. J. Pharm. Sci. 97(10) 2008: 4167-4183.
43. Walker A, et al. Antiserum Albumin Domain Antibodies in the Development of Highly Potent, Efficacious, and Long-Acting Interferon. Protein Eng. Des Sel 23(4) 2010: 271-278.
44. Carter PJ. Introduction to Current and Future Protein Therapeutics: A Protein Engineering Perspective. Exp. Cell Res. 317(9) 2011: 1261-1269.